The Quantellect read.As of Nov 19, 2026, 13 active firms cover Palvella Therapeutics, Inc: 13 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $133.00 to $250.00, a moderate spread. The average target of $196.75 sits 34% above the current $146.72. The rating mix has stayed broadly stable, with Buy-side ratings easing from 14 to 13 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.10 next quarter toward $-7.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Buy
Strong Buy18%
Buy1292%
Neutral00%
Sell00%
Strong Sell00%
Based on 13 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$196.75
+34.1% upside
Average target across 12 active firms as of Nov 19, 2026 vs $146.72 current
Highest Target$250.00
Average Target$196.75
Lowest Target$133.00
Detailed analyst forecasts for PVLA
Showing 1–14 of 14 named analysts shown · 13 active firms in the rating projection
As of Nov 19, 2026, 13 of 13 active firms rate PVLA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PVLA EPS & revenue forecast
EPS · NEXT QUARTER
$-2.10
Range $-2.40 – $-1.70 · 6 analysts · +75% YoY
Next period, 6 analysts expect Palvella Therapeutics, Inc to earn $-2.10 a share (range $-2.40 – $-1.70), versus $-1.20 a year earlier. Full-year consensus is $-6.05, growing to $-7.77 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $22.0M next year.
Top analysts covering Palvella Therapeutics, Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PVLA.
#1
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$246.00+67.7% to target
Overall win rate
45%
+ Follow
#2
SL
Sudan Loganathan
Stephens & Co. · Rank #80
Buy
$220.00+49.9% to target
Overall win rate
47%
+ Follow
#3
Geulah Livshits
Chardan Capital · Rank #104
Buy
$240.00+63.6% to target
Overall win rate
43%
+ Follow
#4
Josh Schimmer
Cantor Fitzgerald · Rank #132
Buy
$200.00+36.3% to target
Overall win rate
44%
+ Follow
#5
Graig Suvannavejh
Mizuho · Rank #239
Buy
$232.00+58.1% to target
Overall win rate
40%
+ Follow
PVLA stock forecast FAQ
What is PVLA's average 12-month price target?+
The 12 active firms with a live target average $196.75 for Palvella Therapeutics, Inc over the next 12 months, ranging from a $250.00 high to a $133.00 low, as of Nov 19, 2026.
Is PVLA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 13 active firms as of Nov 19, 2026, 13 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PVLA?+
The Street-high target is $250.00 (Mizuho), and the Street-low is $133.00 (TD Cowen). The average of all 12 active-firm targets is $196.75.
How many active Wall Street firms cover PVLA?+
13 active firms have a recognized rating on Palvella Therapeutics, Inc as of Nov 19, 2026, and 12 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PVLA?+
Among analysts who currently cover PVLA, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #73). Their current call is Buy with a $246.00 target.
What is Palvella Therapeutics, Inc's projected EPS for next quarter?+
The consensus estimate is $-2.10 per share (range $-2.40 – $-1.70) across 6 analysts. Full-year EPS is projected at $-6.05, rising to $-7.77 the following year.
How much revenue is Palvella Therapeutics, Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $22.0M next year.
Have analysts been upgrading or downgrading PVLA lately?+
As of Nov 19, 2026, 13 of 13 active firms rate PVLA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PVLA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.